Abstract: | In a recent editorial, Bagwe et al.1 discussed the role of cardiacbiomarkers regarding treatment and outcomes of patients withevolving myocardial infarction (MI) in the context of the SYNERGYtrial.2 High-risk acute coronary syndrome (ACS) patients withelevated cardiac troponin (cTnT) benefit from early invasivetherapy, glycoprotein IIb/IIIa inhibitors, combined anti-plateletagent treatment, and the use of low molecular-weight heparins.However, while cTnT measurement |